Autopsy report · NCT01901718

An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.

“Enrollment was more challenging than anticipated.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

International Clinical Research Institute

Sponsor type

University, hospital or other

Conditions

Breakthrough Pain

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Effect of Lap-Band Induced Weight Loss on Serum PSA Levels
  “enrollment challenges” (76% match in meaning)
• Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
  “difficult enrollment” (72% match in meaning)
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
  “Major challenge for enrollment of participants.” (70% match in meaning)
• Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
  “Enrollment challenges, study not feasible” (70% match in meaning)
• The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
  “Difficulties with enrollment.” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.